ADCETRIS

Indicaton

SeaGen's lead product ADCETRIS® (brentuximab vedotin) is marketed in over 70 countries worldwide for the treatment of CD30-expressing lymphomas, in collaboration with Takeda Pharmaceutical Company Limited.

Therapeutic indications

Oncology

Type of product

Antibody

Table

Phase

Marketed
Partnering status

Partnered
Partner

Takeda Pharmaceutical Company Limited.
Available in

EU, US, LATAM, JAPAC, Switzerland

You may also be interested in

MV-002

MV-002 is an orally available modified live biotherapeutic converting the majority of solid tumor patients refractory to immune checkpoint blockade (ICB) to responders. MV002 in combination with different ICB significantly increases the percentage of responding animals (e.g. anti-PD-L1 monotherapy, from 25-30% to 70/80% with MV-002 in translational models of solid tumor).

Discovery

4D Lifetest LungDx

4D Lifetest Lung DX is used as a verification assay to increase the overall sensitivity for the diagnosis of lung cancer for symptomatic patients in combination with other lung cancer specific diagnostics.

Marketed

TOP-N53, TOP-V122, TOP-M119 and TOP-N44

TOPADUR has discovered and developed new dual-acting drugs that target the cGMP-Enzyme Regulation System to stimulate microcirculation, enable tissue regeneration, and avoid local oxygen deficiency. Based on our key invention we have developed an attractive portfolio of drug candidates to treat aging-related diseases as chronic wounds, glaucoma, colorectal cancer, hair loss and skin aging.

Phase I started